← GIP/GLP-1 & amylin agonists × body weight & composition

TrialJAMA2022

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.

Dominik Dahl et al.PubMed ↗Full text ↗Publisher ↗

The primary results report of NCT04039503.

What the trial testedrandomised · 475 people · 2022

Randomised comparison

Probably lowered body weight & composition

−7.10kg−8.70 to −5.40

As reported

difference −7.1 kg, 95% CI −8.70 to −5.40

Randomised comparison

Probably lowered body weight & composition

−9.10kg−10.7 to −7.50

As reported

difference −9.1 kg, 95% CI −10.7 to −7.50

Randomised comparison

Probably lowered body weight & composition

−10.5kg−12.1 to −8.80

As reported

difference −10.5 kg, 95% CI −12.1 to −8.80

Three numbers in the abstract

the abstract, start to end

… 1.6 kg with placebo (5 mg: difference, -7.1 kg [95% CI, -8.7 to -5.4]; 10 mg: difference, -9.1 kg [95% CI, -10.7 to -7.5]; 15 mg: difference, -10.5 kg [95% CI, -12.1 to -8.8]; …

← favours treatmentfavours comparator →
could be chance
Body weight & composition
−7.1−8.70 to −5.40
Body weight & composition
−9.1−10.7 to −7.50
Body weight & composition
−10.5−12.1 to −8.80
GIP/GLP-1 & amylin agonistsBody weight & composition

GIP/GLP-1 & amylin agonists × body weight & compositionhelps?replicated

unlikelylikely
1.001.00 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

315 papers cite itlatest 60 shown

2022
…
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 35133415